Vancouver, British Columbia and Rehovot, Israel — March 5, 2026 — Leads & Copy — BioHarvest Sciences Inc. (NASDAQ: BHST) has announced changes to its Board of Directors. David Tsur will step down after four years of service, while Prof. Hezi Levy has been appointed, effective immediately.
Tsur, a board member since 2021, contributed to the company’s strategic development and governance during a period of operational expansion, capital formation, product commercialization, and market positioning.
Chairman of BioHarvest, Zaki Rakib, thanked Tsur for his leadership, experience, and dedication over the past four years, noting his wisdom and guidance supported BioHarvest’s growth and strategic evolution.
Prof. Levy brings decades of leadership experience across Israel’s healthcare system. A physician by education, he previously served as Director General of the Israeli Ministry of Health, including during the COVID-19 pandemic, where he guided national healthcare policy.
Levy also served as Head of the Medical Corps of the Israel Defense Forces (IDF) with the rank of Brigadier General and was the General Manager of Barzilai Medical Center for many years.
Rakib said the company is honored to welcome Prof. Levy to the BioHarvest Board. He added that Levy’s medical expertise, executive leadership and experience managing large healthcare systems will add significant strength to its governance as they execute their scaling of their direct-to-consumer products business while advancing their high-value biotechnology CDMO platform.
BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds without the need to grow the underlying plant. It is developing therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements.
Source: BioHarvest
